GlycoNex Expands GNX102 Patents in Japan, South Korea, Russia, and Taiwan

GlycoNex, a biotechnology company based in New Taipei City, Taiwan, has announced that it has been granted multiple global patents for its humanized monoclonal antibody, GNX102, in Japan, South Korea, Russia, and Taiwan. These new patents come in addition to a previously awarded U.S. patent by the United States Patent and Trademark Office (USPTO), under U.S. Patent No. 1440967, which covers the composition of matter claims for GNX102.

GNX102 is engineered to target tumor-associated carbohydrate antigens (TACAs) found on cancer cells, aiming to inhibit tumor growth. The antibody has completed Phase 1 clinical trials, showing strong safety and promising efficacy results. According to GlycoNex's CEO, Dr. Mei-Chun Yang, the global patent approvals validate the unique chemical structure and distinct properties of GNX102, which is designed to bind to abnormal glycan molecules on cancer cells.

Dr. Yang emphasized that the Phase 1 trials have indicated GNX102's potential in treating various high-incidence cancers, including those of the stomach, bladder, pancreas, and lungs. The company is optimistic about the ongoing clinical program and anticipates advancing GNX102 as an antibody-drug conjugate (ADC) to later-stage trials.

GNX102 ADCs combine proprietary monoclonal antibodies with cytotoxic drugs to specifically target and destroy cancer cells. This innovative approach not only binds antibodies to cancer cell antigens but also initiates cell death while delivering cytotoxic drugs directly to the tumor, thereby maximizing therapeutic impact and minimizing harm to healthy cells.

GlycoNex Inc. is dedicated to advancing cancer therapies that utilize glycan-targeting mechanisms to effectively curb tumor growth with minimal side effects. The company's research pipeline is spearheaded by GNX102, a humanized monoclonal antibody designed to bind to cancer-specific sugar molecules. The completion of Phase 1 clinical trials for GNX102 has provided compelling data on its safety and efficacy. GlycoNex is also progressing with a range of antibody-drug conjugates (ADCs) that aim to precisely target cancer cells, thereby sparing healthy tissue.

Founded in New Taipei City, Taiwan, GlycoNex is committed to developing innovative cancer therapies that offer new hope for patients with high-incidence cancers.